Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 3—March 2019

Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis

Muhammad OsmanComments to Author , Elizabeth P. Harausz, Anthony J. Garcia-Prats, H. Simon Schaaf, Brittany K. Moore, Robert M. Hicks1, Jay Achar, Farhana Amanullah, Pennan Barry, Mercedes Becerra, Domnica I. Chiotan, Peter C. Drobac2, Jennifer Flood, Jennifer Furin, Medea Gegia, Petros Isaakidis, Andrei Mariandyshev, Iveta Ozere, N. Sarita Shah3, Alena Skrahina, Elena Yablokova, James A. Seddon4, Anneke C. Hesseling4, and for The Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR TB
Author affiliations: Stellenbosch University, Cape Town, South Africa (M. Osman, A.J. Garcia-Prats, H.S. Schaaf, J.A. Seddon, A.C. Hesseling); State University of New York Upstate Medical University, Syracuse, New York, USA (E.P. Harausz); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (B.K. Moore); University of California, San Francisco, California, USA (R.M. Hicks); Médecins Sans Frontières, London, UK (J. Achar); Indus Hospital, Karachi, Pakistan (F. Amanullah); California Department of Public Health, Richmond, California, USA (P. Barry, J. Flood); Harvard Medical School, Boston, Massachusetts, USA (M. Becerra, P.C. Drobac, J. Furin); Romanian National TB Program, Bucharest, Romania (D.I. Chiotan); World Health Organization, Geneva, Switzerland (M. Gegia); Médecins Sans Frontières, Mumbai, India (P. Isaakidis); Northern State Medical University, Arkhangelsk, Russia (A. Mariandyshev, E. Yablokova); Riga Eastern Clinical University Hospital, Riga, Latvia (I. Ozere); Albert Einstein College of Medicine, Bronx, New York, USA (N.S. Shah); Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus (A. Skrahina); Imperial College London, London (J.A. Seddon)

Main Article

Table 1

Overview of 14 studies and 37 children with confirmed cases of extensively drug-resistant tuberculosis*

Reference Country No. persons in study No. children with XDR TB Study design
Amanullah, unpub. data Pakistan 29 1 Retrospective cohort
Banerjee et al. (10) USA 18 1 Retrospective cohort
Chiotan, unpub. data Romania 17 1 Retrospective cohort
Drobac et al. (11) Peru 36 4 Retrospective cohort
Gegia et al. (12) Georgia 55 3 Retrospective cohort
Hicks et al. (13) South Africa 82 5 Retrospective cohort
Isaakidis et al. (14) India 8 2 Retrospective cohort
Kuksa et al. (15) Latvia 53 4 Retrospective cohort
Smirnova et al. (16) Russia 38 1 Retrospective cohort
Moore et al. (17) South Africa 339 5 Retrospective cohort
Seddon et al. (18) South Africa 88 5 Retrospective cohort
Seddon et al. (19) South Africa 131 2 Prospective cohort
Skrahina, unpub. data Belarus 5 2 Retrospective cohort
Swaminathan et al. (20) Tajikistan 27 1 Retrospective cohort

*Each study population involved all consecutively presenting bacteriologically confirmed and clinically diagnosed patients. XDR TB, extensively drug-resistant tuberculosis.

Main Article

  1. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006;81:4302.PubMedGoogle Scholar
  2. World Health Organization. Global Tuberculosis Report 2017. Geneva: The Organization; 2017.
  3. Jenkins  HE, Tolman  AW, Yuen  CM, Parr  JB, Keshavjee  S, Pérez-Vélez  CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383:15729. DOIPubMedGoogle Scholar
  4. Dodd  PJ, Sismanidis  C, Seddon  JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193201. DOIPubMedGoogle Scholar
  5. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva: The Organization; 2016.
  6. Harausz  EP, Garcia-Prats  AJ, Law  S, Schaaf  HS, Kredo  T, Seddon  JA, et al.; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591. DOIPubMedGoogle Scholar
  7. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva: The Organization; 2014.
  8. Wiseman  CA, Gie  RP, Starke  JR, Schaaf  HS, Donald  PR, Cotton  MF, et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J. 2012;31:34752. DOIPubMedGoogle Scholar
  9. World Health Organization. Definitions and reporting framework for tuberculosis. 2013 revision. Geneva: The Organization; 2014.
  10. Banerjee  R, Allen  J, Westenhouse  J, Oh  P, Elms  W, Desmond  E, et al. Extensively drug-resistant tuberculosis in california, 1993-2006. Clin Infect Dis. 2008;47:4507. DOIPubMedGoogle Scholar
  11. Drobac  PC, Mukherjee  JS, Joseph  JK, Mitnick  C, Furin  JJ, del Castillo  H, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117:20229. DOIPubMedGoogle Scholar
  12. Gegia  M, Jenkins  HE, Kalandadze  I, Furin  J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis. 2013;17:6249. DOIPubMedGoogle Scholar
  13. Hicks  RM, Padayatchi  N, Shah  NS, Wolf  A, Werner  L, Sunkari  VB, et al. Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children. Int J Tuberc Lung Dis. 2014;18:107483. DOIPubMedGoogle Scholar
  14. Isaakidis  P, Paryani  R, Khan  S, Mansoor  H, Manglani  M, Valiyakath  A, et al. Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India. PLoS One. 2013;8:e68869. DOIPubMedGoogle Scholar
  15. Kuksa  L, Riekstina  V, Leimane  V, Ozere  I, Skenders  G, Van den Bergh  R, et al. Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action. 2014;4(Suppl 2):S4753. DOIPubMedGoogle Scholar
  16. Smirnova  PA, Turkova  A, Nikishova  EI, Seddon  JA, Chappell  E, Zolotaya  OA, et al. Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study. Eur Respir J. 2016;48:14969. DOIPubMedGoogle Scholar
  17. Moore  BK, Anyalechi  E, van der Walt  M, Smith  S, Erasmus  L, Lancaster  J, et al. Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa, 2005-2010. Int J Tuberc Lung Dis. 2015;19:6639. DOIPubMedGoogle Scholar
  18. Seddon  JA, Hesseling  AC, Willemse  M, Donald  PR, Schaaf  HS. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis. 2012;54:15766. DOIPubMedGoogle Scholar
  19. Seddon  JA, Hesseling  AC, Godfrey-Faussett  P, Schaaf  HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69:45864. DOIPubMedGoogle Scholar
  20. Swaminathan  A, du Cros  P, Seddon  JA, Quinnell  S, Bobokhojaev  OI, Dusmatova  Z, et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. Int J Tuberc Lung Dis. 2016;20:4748. DOIPubMedGoogle Scholar
  21. Dodd  PJ, Yuen  CM, Sismanidis  C, Seddon  JA, Jenkins  HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898906. DOIPubMedGoogle Scholar
  22. Marais  BJ, Gie  RP, Schaaf  HS, Hesseling  AC, Enarson  DA, Beyers  N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis. 2006;10:7328.PubMedGoogle Scholar
  23. Marcy  O, Ung  V, Goyet  S, Borand  L, Msellati  P, Tejiokem  M, et al. Performance of Xpert MTB/RIF and alternative specimen collection methods for the diagnosis of tuberculosis in HIV-infected children. Clin Infect Dis. 2016;62:11618. DOIPubMedGoogle Scholar
  24. Zar  HJ, Workman  L, Isaacs  W, Munro  J, Black  F, Eley  B, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis. 2012;55:108895. DOIPubMedGoogle Scholar
  25. Detjen  AK, Walters  E. Editorial commentary: improving children’s access to new tuberculosis d iagnostic tools starts with the collection of appropriate specimens. Clin Infect Dis. 2016;62:116971. DOIPubMedGoogle Scholar
  26. Marais  BJ, Gie  RP, Schaaf  HS, Hesseling  AC, Obihara  CC, Starke  JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8:392402.PubMedGoogle Scholar
  27. Seddon  JA, Thee  S, Jacobs  K, Ebrahim  A, Hesseling  AC, Schaaf  HS. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect. 2013;66:3209. DOIPubMedGoogle Scholar
  28. Seddon  JA, Godfrey-Faussett  P, Jacobs  K, Ebrahim  A, Hesseling  AC, Schaaf  HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40:127786. DOIPubMedGoogle Scholar
  29. Zhang  Z, Liu  M, Wang  Y, Pang  Y, Kam  KM, Zhao  Y. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China. Eur J Clin Microbiol Infect Dis. 2014;33:195966. DOIPubMedGoogle Scholar
  30. Schaaf  HS, Seddon  JA, Caminero  JA. Second-line antituberculosis drugs: current knowledge, recent research findings and controversies. Progr Respir Res. 2011;40:8195. DOIGoogle Scholar
  31. Kam  KM, Yip  CW, Cheung  TL, Tang  HS, Leung  OC, Chan  MY. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist. 2006;12:711. DOIPubMedGoogle Scholar
  32. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. Geneva: The Organization; 2016.
  33. Achar  J, Hewison  C, Cavalheiro  AP, Skrahina  A, Cajazeiro  J, Nargiza  P, et al. Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis. Emerg Infect Dis. 2017;23:17113. DOIPubMedGoogle Scholar
  34. Gandhi  NR, Moll  A, Sturm  AW, Pawinski  R, Govender  T, Lalloo  U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:157580. DOIPubMedGoogle Scholar
  35. Gandhi  NR, Andrews  JR, Brust  JC, Montreuil  R, Weissman  D, Heo  M, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2012;16:907. DOIPubMedGoogle Scholar
  36. Dheda  K, Shean  K, Zumla  A, Badri  M, Streicher  EM, Page-Shipp  L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798807. DOIPubMedGoogle Scholar
  37. Pietersen  E, Ignatius  E, Streicher  EM, Mastrapa  B, Padanilam  X, Pooran  A, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383:12309. DOIPubMedGoogle Scholar
  38. Chiang  SS, Khan  FA, Milstein  MB, Tolman  AW, Benedetti  A, Starke  JR, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:94757. DOIPubMedGoogle Scholar
  39. Zhang  X, Falagas  ME, Vardakas  KZ, Wang  R, Qin  R, Wang  J, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7:60315.PubMedGoogle Scholar
  40. Ahuja  SD, Ashkin  D, Avendano  M, Banerjee  R, Bauer  M, Bayona  JN, et al.; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300. DOIPubMedGoogle Scholar
  41. Falzon  D, Gandhi  N, Migliori  GB, Sotgiu  G, Cox  HS, Holtz  TH, et al.; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:15668. DOIPubMedGoogle Scholar
  42. Migliori  GB, Sotgiu  G, Gandhi  NR, Falzon  D, DeRiemer  K, Centis  R, et al.; “The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB”. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2013;42:16979. DOIPubMedGoogle Scholar

Main Article

1Current affiliation: University of California, San Francisco, California, USA.

2Current affiliation: Oxford University, Oxford, UK.

3Current affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

4These senior authors contributed equally to this article.

Page created: February 19, 2019
Page updated: February 19, 2019
Page reviewed: February 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.